The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Allogeneic transplantation in FLT3-mutated AML: current role and future directions
Robert Negrin, MD, Stanford University, Stanford, CA, discusses the role of allogeneic stem cell transplantation in patients with FLT3-mutated acute myeloid leukemia (AML) achieving first remission. He explains why transplant remains the preferred approach for most eligible patients despite advances in targeted therapies, while also outlining the clinical and logistical factors that may influence decision-making, including age, comorbidities, donor availability, and transplant feasibility. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, whether to proceed to transplant in these patients has traditionally been the answer is yes. We generally prefer to proceed to transplant. The situations where we may consider that recommendation often have to do more with whether the candidate is a good candidate for a transplant. For example, what is their age? What are their comorbidities? What type of donor do we have available for their use? And whether transplant is logistically feasible in their care...
Yes, whether to proceed to transplant in these patients has traditionally been the answer is yes. We generally prefer to proceed to transplant. The situations where we may consider that recommendation often have to do more with whether the candidate is a good candidate for a transplant. For example, what is their age? What are their comorbidities? What type of donor do we have available for their use? And whether transplant is logistically feasible in their care. But in a general sense, we do prefer to move these patients on to transplant because we do feel that that data is relatively clear that transplant in that patient population is effective and useful. Of course, with more use of these different inhibitors and longer-term follow-up, those recommendations can change. But at the current time, our general approach is to move these patients forward to transplant and then to use a FLT3 inhibitor as maintenance therapy as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
